Why the study?
The stability and effectiveness of the formalin-inactivated EV-A71 whole virion when stored long-term at low temperature remained undetermined beyond its current 18-month shelf life.
The FI-EV-A71 vaccine maintains decent stability and good immunogenicity after ten years of low temperature storage, facilitating flexibility in manufacturing.
Answers are grounded in this paper and cite their sources.
Supports long-term FI-EV-A71 vaccine stockpiling; extends feasibility for distribution in endemic regions.
BACKGROUND: Vaccine stability is an important issue for vaccine development, which affects whether the vaccine product is effective within a certain period of time in each progress. Hand, foot, and mouth diseases (HFMD) is an epidemic disease in young children usually caused by Enterovirus A group viruses, and the Enterovirus A71 (EV-A71) had caused several pandemics and public health issues around the world. After two decades of research and development, formalin-inactivated EV-A71 (FI-EV-A71) vaccines are the first to complete the phase III clinical trials for protection against EV-A71 infection. Currently, the shelf life of FI-EV-A71 vaccine product is set to be within 18 months, but the stability and the effectiveness of the FI-EV-A71 whole virion when stored long-term at low temperature remains undetermined. METHODS: Assessing the long-term storage properties of viral particles facilitates flexibility in manufacturing of vaccine products. In this study, the stability profiles of FI-EV-A71 vaccine lots and bulks after long-term of low temperature storage were analyzed by protein tests, particle measurement and animal immunization study. RESULTS: After over ten years of storage, the reduction of protein concentration in the FI-EV-A71 bulk samples is less than 30 % and the antigenic content remained in a suspended, particulate state. Both the packed FI-EV-A71 final vaccine products and the FI-EV-A71 antigens adjuvant premix bulk could elicit strong neutralizing responses in mice. CONCLUSION: After ten years of low temperature storage, the FI-EV-A71 vaccine still presents decent stability and good immunogenicity.
No takes yet. Share an insight, caveat, or question.
Shen et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: